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incidence
The crude incidence of cervical cancer in the European Union
is 13.2/100 000 and the crude mortality rate is 5.9/100 000
women/year.
diagnosis
Pathological diagnosis should be made according to the World
Health Organization classification based on a surgical biopsy.
staging
Routine staging includes clinical with gynecological
examination, blood counts, routine chemistry including renal
and liver function tests. MRI is superior to CT scan for tumor
extension assessment and MRI is equal to CT scan for nodal
assessment. MRI should be preferred to CT scan and include
pelvic and abdominal imaging [III, A]. A thoracic CT scan may
be included for metastasis assessment. SCC dosage in squamous
cell carcinoma may be useful in patient follow-up if initially
increased. Surgical pelvic and para-aortic nodal staging are
optional and PET is under evaluation.
The most widely used classification is FIGO (Fe´de´ration
Internationale de Gyne´cologie et d’Obste´trique) based on
clinical examination.
treatment
Multidisciplinary treatment planning is mandatory, based on
tumor size and extension.
FIGO stage IA1
Standard treatment consists of conization with free margins or
simple hysterectomy (according to patient age) [III, B]. In the
case of lympho-vascular space involvement, pelvic
lymphadenectomy is recommended [III, B]. In patients with
pelvic node involvement, standard treatment consists of
complementary concomitant chemoradiation [I, B].
FIGO stage IA2
Surgery is the standard. Options consist of conization or
trachelectomy in young patients and simple or radical
hysterectomy in other patients [III, B]. Pelvic
lymphadenectomy is required [III, B]. In patients with pelvic
node involvement, standard treatment consists of
complementary concomitant chemoradiation [I, B].
FIGO stage IB1
There is no standard treatment. Options consist of surgery,
external irradiation plus brachytherapy or combined radio-
surgery [III, B].
Standard surgery consists of radical hysterectomy, bilateral
oophorectomy (optional) and pelvic lymphadenectomy.
Conservative surgery can be proposed for a tumor with
excellent prognostic factors. Combined radio-surgery usually
consists of preoperative brachytherapy followed 6–8 weeks later
by surgery. In patients treated with upfront surgery or
preoperative brachytherapy followed by surgery
presenting pelvic node involvement, standard treatment
consists of complementary concomitant chemoradiation
[I, B].
FIGO stage IB2–IVA
Concomitant chemoradiation represents the standard [I, A].
This modality is superior to radiotherapy alone for local
control, metastasis rate, disease-free and overall survival, with
an increase in toxic (gastrointestinal and haematological)
side-effects [I, A]. Patients with advanced stage III and IVA
may benefit less than patients with stage IB2–IIA/B.
Platinum-based regimens for chemoradiation remain the
standard. External irradiation is combined with
brachytherapy and the total treatment duration should remain
<55 days [III, B]. Complementary extrafascial hysterectomy
is an option.
Neoadjuvant chemotherapy remains controversial and is
currently under investigation by the EORTC (55994).
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FIGO stage IVB
Platinum-based combination chemotherapy has potential
benefit [III, B].
locoregional and metastatic recurrence
For most patients palliative chemotherapy is the standard
option. Pelvic surgery (exenteration in most cases) and
radiotherapy are an option in selected cases.
follow-up
Clinical with gynaecological examination including PAP smear
(cave changes in patients irradiated) are performed every 3
months for the first 2 years, every 6 months for the next 3 years
and yearly thereafter [III, C].
note
Levels of evidence [1–IV] and grades of recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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